KRAS mutation fails to predict NSCLC chemotherapy success

Research casts doubt on the ability of the KRAS mutation to aid the selection of patients with non-small-cell lung cancer to receive adjuvant chemotherapy.
Source: MedWire News - Oncology - Category: Cancer & Oncology Source Type: news